Could this FTSE 100 stock double your money again?

G A Chester discusses the outlook for this FTSE 100 (INDEXFTSE:UKX) big winner and a smaller-cap peer.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Investors who bought into the Hikma Pharmaceuticals(LSE: HIK) turnaround story at the lows early last year doubled their money before the year was out. The shares have since retreated from their peak, and are off another few percentage points today after the FTSE 100 firm’s annual results.

However, could the stock be set for another big upsurge, alongside small-cap peer Alliance Pharma (LSE: APH), whose shares have seen an even bigger pullback since soaring last year?

Growth across the board

Hikma posted strong results today. These followed leadership changes and a major overhaul of the business, including the consolidation of its Generics manufacturing facilities and US distribution facilities.

Group revenue increased 7% to $2.1bn, with core operating profit up 19% to $460m, and core earnings per share (EPS) rising 31% to $1.378 (104.4p at current exchange rates). The board lifted the dividend 12% to $0.38 (28.8p).

All three of its businesses — Injectables, Generics and Branded — increased their revenues and profits. And there was growth across all three of its geographical regions: US (62% of group revenue); Middle East and North Africa (32%); and Europe and Rest of World (6%).

Very optimistic

Hikma’s shares are trading at 1,580p, as I’m writing, which is 22% below last year’s high of 2,025p. The trailing price-to-earnings (P/E) ratio is 15.1 and the dividend yield is 1.8%. While the yield is admittedly skinny, the P/E is reasonable for a blue-chip stock in the defensive pharma sector.

Furthermore, Hikma’s transformational changes and strong performance in 2018 have new chief executive Siggi Olafsson “confident that we can build on this momentum going forward,” and executive chairman Said Darwazah “very optimistic for the future.”

I can’t see Hikma’s shares doubling again in the space of a year, but with the business back on track, the longer-term outlook appears promising. I rate the stock a ‘buy’.

Unmerited de-rating

Alliance Pharma has a growing portfolio of pharmaceutical and consumer healthcare products it owns or licenses the rights to. It sells these products in more than 100 countries.

Its shares are trading at 65p, down 36% from last year’s high of 102p. I’m at a loss to understand quite why the stock has slumped so far. A £0.7m step-up in its future annual cost base, due to a raft of regulatory and accounting changes, hardly seems sufficient to merit such a de-rating. There was a hefty share sale by company founder (and now a non-executive director) John Dawson in November, but the shares had already completed much of their decline by that date.

Further growth ahead

In a trading update in January, ahead of annual results scheduled for release a week on Tuesday, Alliance said 2018 revenue was £124m — up 22% on the prior year, or up 4% excluding acquisitions. It also said “underlying profit before tax is expected to be in line with [unspecified] expectations” and that “free cash flow for the year was slightly stronger than anticipated at approximately £16.1m.”

A research note dated November on its corporate website has underlying profit before tax of £28.9m, free cash flow of £15.5m, underlying EPS of 4.66p (10% ahead of 2017), and a dividend of 1.46p (also up 10%). At the current share price, the P/E is 13.9 and the dividend yield is 2.25%.

I see the shares as very buyable, with the company having said in January: “We look forward to delivering further growth in the year ahead.”

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended Alliance Pharma and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Here’s why this FTSE 100 gem still looks a huge bargain to me despite a 94% rise this year

A stock can still have huge value even after a substantial rise in price. To find out if this is…

Read more »

Young black man looking at phone while on the London Overground
Investing Articles

Investing £3.33 into an ISA every day from 22 could result in a £60,000 passive income

Millions of Britons use the Stocks and Shares ISA as a way to build wealth and generate an income. However,…

Read more »

Investing Articles

2 resurgent cheap shares that could skyrocket in 2025

Cheap shares can take our portfolios to the next level. Here, Dr James Fox highlights two stocks that appear to…

Read more »

Investing Articles

How much does an investor need in a Stocks and Shares ISA to earn £1,000 a month in passive income?

A Stocks and Shares ISA's a valuable asset for investors. Not having to pay dividend tax can be a big…

Read more »

Investing Articles

9% dividend yield! Could buying this FTSE 250 stock earn me massive passive income?

Assura looks like an outstanding stock for dividend investors to consider. But is the 9% dividend yield the passive income…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Why I think this month could be critical for the Lloyds share price!

Our writer explains why he thinks the bank's 2024 results will have a significant impact on the short-term direction of…

Read more »

British Pennies on a Pound Note
Investing Articles

This former penny share has soared 168%. Is the best yet to come?

When Christopher Ruane saw a penny share as a potential bargain last year, he was spot on. So having not…

Read more »

Mature couple at the beach
Investing Articles

£20k in an ISA? Here’s how it could generate £1 of passive income every hour — forever

With a long-term approach, Christopher Ruane explains how an investor could aim to earn a pound per hour in passive…

Read more »